Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SSD8432 in Healthy Adults
NCT05339646Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of simnotrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: The Adverse events of SSD8432. Status: unknown.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05339646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339646.